| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WASHINGTON—Leading scientists, public policy experts and biotech industry leaders joined forces recently to launch Working to Fight AMR, a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance (AMR)—it will also advocate for policies that catalyze the creation of new medicines.
 
“Antimicrobial resistance already poses a grave threat to human health, and it is a looming public health emergency," said Dr. Greg Frank, director of infectious disease policy at the Biotechnology Innovation Organization, who is heading up the coalition. "Working to Fight AMR will advocate for policies that create a sustainable ecosystem and boost investment in this deeply neglected area.”
 
Scientists have developed only one truly novel antibiotic since 1984. For most companies, investing in AMR research does not make sense, as new treatments would be used sparingly. Companies risk not generating enough revenue to recoup development costs. Globally, just 1 percent of experimental medicines aim to fight bacterial infections.
 
“We're eager to mobilize this diverse community of stakeholders, including patients, to implement practical policy solutions to combat superbugs,” Frank added. “Together, we can save millions of lives.”

Related Topics

Published In

Volume 15 - Issue 10 | October 2019

October 2019

October 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue